Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
Authors' conclusion
Liraglutide and diet reduce weight, insulin resistance and PAI-1. Liraglutide, sitagliptin and diet do not change FMD in obese individuals with prediabetes with normal endothelial function. Liraglutide alone lowers the pro-inflammatory and pro-atherosclerotic chemokine MCP-1, indicating that this beneficial effect is independent of weight loss.
Study context
- Population
- Individuals with obesity and prediabetes
- Participants
- 88 individuals
- Comparison
- Liraglutide vs hypocaloric diet vs sitagliptin
- Liraglutiden = 44
- Dietn = 22
- Sitagliptinn = 22
- Primary endpoint
- Measures of endothelial function: flow-mediated vasodilation (FMD), PAI-1 and urine albumin-to-creatinine ratio (UACR)
- Follow-up
- 14 weeks
Methodological detailsdouble-blind (drug), placebo-controlled, 2:1:1 randomization, Measurements at baseline, after 2 weeks (prior to significant weight loss) and after 14 weeks
- Double-blind (drug)
- Placebo-controlled
- 2:1:1 randomization
- Measurements at baseline, after 2 weeks (prior to significant weight loss) and after 14 weeks
Primary result
As reported in the abstract
FMD, PAI-1 and UACR
- Liraglutide and diet reduced PAI-1, while sitagliptin did not
- No significant effect of any treatment on FMD
- No effect of treatment on urine albumin-to-creatinine ratio (UACR)
Further findings
Weight and insulin resistance
- Liraglutide and diet reduced weight and insulin resistance, while sitagliptin did not
FMD in subgroup with baseline FMD below median
- Improvement in FMD by all three treatments
- Post hoc subgroup analysis
GLP-1R antagonism with exendin (9-39)
- Increased fasting blood glucose but did not change FMD or PAI-1
MCP-1
- Liraglutide, but not sitagliptin or diet, reduced MCP-1
Original publication
Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial. Diabetes Obes Metab. Published 10 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →